Epigenetics in Drug Discovery

Date: Monday, 6 March 2017 - Tuesday, 7 March 2017
Location: Wellcome Genome Campus Conference Centre, Cambridge, UK

Keynote Speakers

James Audia
Chief Scientific Officer, Constellation Pharmaceuticals

Danica Fujimori
Principal Investigator, University of California, San Francisco

Dafydd Owen
Associate Research Fellow, Pfizer Ltd

Stefan Knapp
Professor, Goethe Institut Frankfurt

Overview

SELECTBIO is thrilled to announce the continuation of Epigenetics in Drug Discovery for 2017.

The event will form part of the multi-track conference, Advances in Drug Discovery, and will run alongside three additional tracks: Antibodies in Drug Discovery, Academic Drug Discovery and Stem Cells in Drug Discovery.

As a multi-track event, delegates will have unrestricted access to all conference tracks and networking opportunities. Attracting researchers from both academia and industry, this track will explore the latest opportunities and challenges for epigeneticists looking to discover and develop new molecular entities. Topics to be addressed include, assays for Methyltranferases and Demethylases, Bromodomain inhibitor discovery, indications beyond cancer, Non-BET Bromodomains and of course updates in Oncology.

Thanks to vast steps forwards in this field, epigenetic compounds are becoming more and more common in both pre-clinical and clinical drug discovery. If you work in epigenetics research, you will benefit from the expert knowledge of academic and industry leaders who are pushing the boundaries of drug discovery, whilst networking with the technology providers who are enabling them to do so.

SELECTBIO is offering a limited number of student bursaries at this event. Find out more

Agenda Topics

Assays For Methyltranferases and Demethylases
Bromodomain Inhibitor Discovery
Indications Beyond Cancer
Non-BET bromodomains
Updates From Oncology

Sponsorship and Exhibition Opportunities

Exhibition Team,
exhibitors@selectbio.com
+44 (0) 1206 501654

Confirmed Speakers to date

Cheryl Arrowsmith, Chief Scientist, University of Toronto
Julian Blagg, Deputy Director, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research
Ann Boriack-Sjodin, Senior Director, Protein & Structural Sciences, Epizyme
Amedeo Caflisch, Full Professor, University of Zurich
Sarantis Chlamydas, Product Manager of Epigenetics Services, Active Motif
Alessio Ciulli, Professor, University of Dundee
Andrea Cochran, Principal Scientist, Early Discovery Biochemistry, Genentech
Stuart Conway, Professor, University Of Oxford
Danette Daniels, Group Leader, Promega Corporation
Emmanuel Demont, Director, GlaxoSmithKline
Oleg Fedorov, Team Leader, University of Oxford
Anja Groth, Group Leader, University of Copenhagen
Kilian Huber, Principal Investigator , University of Oxford, Structural Genomic Consortium (SGC)
Phil Humphreys, Senior Scientific Investigator, GlaxoSmithKline
Akane Kawamura, Research Fellow, University Of Oxford
En Li, Head of Biomedical Research, Novartis Institutes for BioMedical Research Inc
Udo Oppermann, Principal Investigator, University of Oxford
Sophie Postel-Vinay, Group Leader, Institut Gustave Roussy
Hendrik Stunnenberg, Professor, Radboud University Nijmegen
Michiel Vermeulen, Professor, Radboud University